Pharmacokinetic Parameters - NAPLEX

1. A 82-year-old woman (weight 50 kg, height 155 cm) is prescribed trimethoprim-sulfamethoxazole (TMP-SMX) for a urinary tract infection. Current medications: warfarin 3 mg PO daily, losartan 50 mg PO daily. Medical history: atrial fibrillation, chronic kidney disease. Allergies: none. Labs: SCr 1.7 mg/dL. The ordered regimen is TMP-SMX double strength (160/800 mg) 1 tablet PO twice daily. How should the dosage be adjusted for this patient's renal function?
   Answer: TMP-SMX DS 1 tablet PO daily The pharmacokinetic concept being tested is renal dose adjustment for antibiotics like TMP-SMX in elderly patients with reduced kidney function. The key patient-specific factor is chronic kidney disease with SCr 1.7 mg/dL, estimating CrCl ≈20 mL/min and prolonging half-life. Choice B is the best because reducing to DS 1 tablet daily halves the dose to prevent accumulation and hyperkalemia. Choice A ignores impairment, risking toxicity; choice C increases dose inappropriately; choice D uses lower strength without adjustment, still excessive. A pearl is to use CrCl = [(140 - age) × weight] / [72 × SCr] × 0.85 for females, and for CrCl 15-30 mL/min, dose TMP-SMX at 50% of normal, monitoring for adverse effects like rash or hematologic changes.
2. A 33-year-old female (weight 65 kg, height 168 cm) with bipolar disorder is taking lithium. Current medications: lithium carbonate 300 mg PO three times daily, ibuprofen 600 mg PO three times daily as needed (started 1 week ago for back pain). Medical history: bipolar I disorder. Allergies: none. Labs: serum creatinine 0.9 mg/dL, sodium 139 mEq/L. A trough lithium concentration (drawn 12 hours after the last dose) is 1.6 mEq/L (high; goal 0.6–1.2 mEq/L). Which factor is most likely to affect lithium clearance in this patient?
   Answer: Decreased lithium clearance due to NSAID-associated reduction in renal prostaglandins This question tests understanding of drug interactions affecting renal clearance of lithium. The key patient-specific factor is the recent addition of ibuprofen (an NSAID) to stable lithium therapy, resulting in an elevated lithium level of 1.6 mEq/L. The correct answer is decreased lithium clearance due to NSAID-associated reduction in renal prostaglandins because NSAIDs inhibit prostaglandin synthesis, which reduces renal blood flow and glomerular filtration rate, thereby decreasing lithium clearance and causing accumulation. Option A incorrectly suggests increased clearance and renal blood flow. Option C incorrectly invokes CYP3A4 inhibition, but lithium is not metabolized by CYP enzymes. Option D incorrectly suggests increased clearance through decreased reabsorption. The clinical pearl is that NSAIDs (except aspirin ≤ 325 mg/day) decrease lithium clearance by 20-25% through prostaglandin inhibition, requiring dose reduction or NSAID discontinuation to prevent toxicity.
3. Doubling an IV dose increases AUC 5-fold. What is the best conclusion?
   Answer: Clearance is dose-dependent With an IV dose, AUC = dose / clearance. If clearance were constant, doubling the dose would double AUC, not increase it 5-fold. The 5-fold AUC rise means clearance fell as dose increased, so clearance is dose-dependent. The tempting answer 'half-life stays unchanged' is wrong because a dose-dependent fall in clearance would also change half-life.
4. A 70-year-old man (weight 88 kg, height 173 cm) is on warfarin for a mechanical heart valve. Current medications: warfarin 5 mg PO daily, amiodarone 200 mg PO daily (started 10 days ago), levothyroxine 75 mcg PO daily. Medical history: mechanical aortic valve, hypothyroidism. Allergies: none. Labs: INR 4.2 (goal 2.5–3.5). Which factor is most likely to affect the drug's clearance in this patient?
   Answer: Amiodarone inhibition decreasing warfarin clearance and increasing INR The pharmacokinetic concept being tested is drug-drug interactions via CYP inhibition affecting warfarin clearance and anticoagulation response. The key patient-specific factor is recent amiodarone initiation, which inhibits CYP2C9 and decreases warfarin clearance. Choice A is the best because it explains the elevated INR due to reduced metabolism, requiring warfarin dose reduction. Choice B is incorrect as levothyroxine does not induce clearance; choice C is wrong because valve type does not affect renal clearance; choice D misinterprets higher INR as increased clearance. A pearl is to reduce warfarin dose by 25-40% with amiodarone, monitoring INR weekly, using Cl = dose / Css to estimate changes and target INR 2.5-3.5 for mechanical valves.
5. Oral loading dose if F=0.7, salt=0.8, Vd=35 L, target=4 mg/L?
   Answer: 250 mg Target amount in the body is 4 mg/L times 35 L = 140 mg. Divide by bioavailability and salt factor: 140 / (0.7 x 0.8) = 140 / 0.56 = 250 mg, so give 250 mg. The tempting 200 mg comes from dividing by 0.7 but forgetting the salt factor 0.8.
6. A drug infusion reaches 93.75% of Css after 5 days. Half-life?
   Answer: 1.25 days After 5 days, 93.75% of steady state is reached, so 6.25% remains. Each half-life cuts the remaining gap in half: 50%, 25%, 12.5%, 6.25%. That means 5 days equals 4 half-lives, so half-life is 5 / 4 = 1.25 days. The tempting 1.67 days comes from assuming 3 half-lives, but that would leave 12.5% remaining, not 6.25%.
7. A 38-year-old man (weight 70 kg, height 175 cm) is treated with linezolid for pneumonia. Current medications: linezolid 600 mg PO every 12 hours, fluoxetine 40 mg PO daily. Medical history: depression. Allergies: none. Labs: SCr 0.9 mg/dL, AST/ALT normal. Which factor is most likely to affect the drug's clearance in this patient?
   Answer: Linezolid clearance is not meaningfully affected by fluoxetine; no major PK interaction expected The pharmacokinetic concept being tested is the absence of significant pharmacokinetic interactions for linezolid, which has mixed renal and non-renal clearance. The key patient-specific factor is concomitant fluoxetine, but it does not alter linezolid's CYP-mediated metabolism meaningfully. Choice C is the best because no major PK interaction occurs, though PD serotonin risks exist separately. Choice A overstates inhibition; choice B ignores renal role; choice D misrepresents induction. A pearl is to assess linezolid clearance (Cl ≈ 7 L/h, unaffected by mild interactions), using dose / AUC for estimates, and monitor for myelosuppression rather than adjusting for fluoxetine PK effects.
8. A 61-year-old woman (weight 68 kg, height 165 cm) with seizures is taking valproic acid. Current medications: divalproex sodium 1,000 mg/day in divided doses, aspirin 81 mg PO daily. Medical history: epilepsy, coronary artery disease. Allergies: none. Labs: albumin 2.5 g/dL (low), total valproic acid level 55 mcg/mL (typical goal 50–100 mcg/mL), AST/ALT normal. Which pharmacokinetic parameter should be monitored during therapy?
   Answer: Free (unbound) valproic acid concentration due to low albumin The pharmacokinetic concept being tested is monitoring free drug concentrations for highly protein-bound agents like valproic acid in hypoalbuminemia. The key patient-specific factor is low albumin (2.5 g/dL), increasing the unbound fraction and risking toxicity at normal total levels. Choice B is the best because free levels better reflect active drug exposure, guiding safer dosing in altered binding states. Choice A assumes constant binding, ignoring hypoalbuminemia; choice C is not standard; choice D focuses on peaks, less relevant for steady-state control. A pearl is to monitor free valproic acid (target 5-15 mcg/mL) when albumin <3.5 g/dL, using fraction unbound fu ≈ 1 / (1 + K × [protein]), and adjust doses accordingly for seizure control.
9. A 67-year-old woman (weight 75 kg, height 168 cm) is prescribed gabapentin for neuropathic pain. Current medications: gabapentin (new), duloxetine 60 mg PO daily. Medical history: diabetic neuropathy, chronic kidney disease. Allergies: none. Labs: SCr 2.4 mg/dL. The prescription is gabapentin 300 mg PO three times daily. How should the dosage be adjusted for this patient's renal function?
   Answer: Gabapentin 300 mg PO once daily The pharmacokinetic concept being tested is renal dose adjustment for gabapentin, primarily eliminated unchanged by the kidneys. The key patient-specific factor is chronic kidney disease with SCr 2.4 mg/dL, estimating CrCl ≈27 mL/min and prolonging half-life. Choice B is the best because reducing to 300 mg daily prevents accumulation and sedation while maintaining analgesia. Choice A ignores adjustment; choice C increases dose; choice D heightens frequency. A pearl is to adjust gabapentin using CrCl, formula [(140 - age) × weight] / [72 × SCr] × 0.85 for females, dosing 100-300 mg daily for CrCl 15-29 mL/min, titrating slowly for neuropathic pain.
10. A 55-year-old woman (weight 92 kg, height 165 cm) is being treated for a pulmonary embolism and needs enoxaparin. Current medications: sertraline 50 mg PO daily, omeprazole 20 mg PO daily. Medical history: obesity, depression. Allergies: none. Labs: SCr 2.3 mg/dL, estimated creatinine clearance is needed for dosing; use Cockcroft-Gault with actual body weight unless otherwise specified. Which factor is most likely to affect the drug's clearance in this patient when selecting an enoxaparin regimen?
    Answer: Elevated serum creatinine indicating reduced renal clearance The pharmacokinetic concept being tested is the impact of renal function on the clearance of anticoagulants like enoxaparin, which is primarily eliminated by the kidneys. The key patient-specific factor is impaired renal function, indicated by an elevated serum creatinine of 2.3 mg/dL and reduced creatinine clearance. Choice A is the best because elevated serum creatinine directly signals decreased renal clearance, necessitating dose adjustment to avoid bleeding risks. Choice B is incorrect as omeprazole does not significantly inhibit CYP2C19 for enoxaparin; choice C is wrong because sertraline does not increase hepatic blood flow; choice D is suboptimal as obesity affects volume of distribution more than hepatic metabolism for enoxaparin. A clinical pearl is to estimate creatinine clearance using Cockcroft-Gault with actual body weight for enoxaparin dosing, CrCl = [(140 - age) × weight (kg)] / [72 × SCr (mg/dL)] × 0.85 for females, and reduce dose by 50% if CrCl <30 mL/min to minimize accumulation.
11. A 72-year-old woman (weight 60 kg, height 160 cm) with atrial fibrillation is receiving digoxin. Current medications: digoxin 0.25 mg PO daily, metoprolol succinate 50 mg PO daily, hydrochlorothiazide 25 mg PO daily. Medical history: heart failure with reduced ejection fraction, chronic kidney disease. Allergies: none. Labs: SCr 1.6 mg/dL, potassium 3.2 mEq/L (low). A digoxin level drawn 8 hours after the last dose is 2.3 ng/mL (goal 0.5–0.9 ng/mL for HF). Which pharmacokinetic parameter should be monitored during therapy?
    Answer: Trough digoxin level at steady state, drawn at least 6 hours after a dose The pharmacokinetic concept being tested is therapeutic drug monitoring for narrow therapeutic index drugs like digoxin, focusing on steady-state trough levels. The key patient-specific factor is chronic kidney disease with SCr 1.6 mg/dL, which prolongs digoxin's half-life and requires careful monitoring to avoid toxicity. Choice B is the best because trough levels at steady state, drawn at least 6 hours post-dose, accurately reflect minimum concentrations and guide dosing adjustments for efficacy and safety in heart failure. Choice A is incorrect as peak levels do not correlate well with therapeutic effects; choice C is suboptimal because urine concentrations are not standard for digoxin monitoring; choice D ignores timing, which is critical for interpreting levels. A transferable pearl is to aim for digoxin troughs of 0.5-0.9 ng/mL in heart failure, using the formula for half-life $t_{1/2}$ = 0.693 × $V_d$ / Cl to estimate time to steady state, typically 5-7 days in normal renal function but longer in impairment.
12. A 52-year-old woman (weight 62 kg, height 160 cm) is started on aminophylline IV for acute asthma exacerbation. Current medications: none. Medical history: asthma. Allergies: none. Labs: SCr 0.7 mg/dL, AST/ALT normal. The pharmacist uses $\text{LD} = C_{\text{target}} \times V_d \times \text{weight}$ with $V_d = 0.5\ \text{L/kg}$ and target theophylline concentration $C_{\text{target}} = 10\ \text{mg/L}$. What is the appropriate loading dose for this patient?
    Answer: 310 mg IV once The pharmacokinetic concept being tested is loading dose calculation for theophylline equivalents using volume of distribution in acute asthma. The key patient-specific factor is normal liver and renal function, supporting standard $V_d$ use without adjustments. Choice B is the best because LD = 10 mg/L × 0.5 L/kg × 62 kg = 310 mg achieves the target theophylline concentration promptly. Choice A underdoses; choice C approximates but exceeds; choice D overdoses significantly. A pearl is to calculate aminophylline LD = $C_{target}$ × $V_d$ × weight / theophylline fraction (∼0.8), but use directly here, followed by infusion rate = Cl × Css, monitoring levels to avoid tachycardia.
13. A 50-year-old man (weight 90 kg, height 178 cm) is being treated for invasive aspergillosis with voriconazole. Current medications: voriconazole 200 mg PO twice daily, rifampin 600 mg PO daily (started yesterday for latent tuberculosis), metformin 1,000 mg PO twice daily. Medical history: type 2 diabetes, latent TB. Allergies: none. Labs: AST/ALT within normal limits, SCr 1.0 mg/dL. Which factor is most likely to affect the drug's clearance in this patient?
    Answer: Rifampin induction increasing voriconazole clearance and lowering exposure The pharmacokinetic concept being tested is enzyme induction affecting hepatic clearance of voriconazole, a CYP3A4 substrate. The key patient-specific factor is concomitant rifampin, a potent CYP3A4 inducer, which increases voriconazole metabolism and reduces exposure. Choice A is the best because rifampin's induction directly lowers voriconazole levels, necessitating dose increases or alternative therapy to maintain antifungal efficacy. Choice B is incorrect as metformin does not inhibit voriconazole clearance; choice C is wrong because diabetes does not increase protein binding; choice D is suboptimal as normal liver enzymes do not preclude induction effects. A pearl is to avoid strong inducers with voriconazole; use the formula for adjusted dose = standard dose / (1 - induction factor), estimating induction impact via level monitoring, and target troughs of 1-5.5 mg/L.
14. A 45-year-old male (weight 90 kg, height 180 cm) with seizure disorder is stable on phenytoin. Current medications: phenytoin extended-release 300 mg PO nightly, omeprazole 20 mg PO daily. Medical history: epilepsy, gastroesophageal reflux disease. Allergies: none. Labs: albumin 4.2 g/dL, AST 24 units/L, ALT 28 units/L. One month after starting trimethoprim-sulfamethoxazole for a skin infection, he develops nystagmus and ataxia. Which factor is most likely to affect phenytoin clearance in this patient?
    Answer: Enzyme inhibition by trimethoprim-sulfamethoxazole causing decreased phenytoin clearance This question tests understanding of drug-drug interactions affecting hepatic metabolism and clearance. The key patient-specific factor is the recent addition of trimethoprim-sulfamethoxazole to a stable phenytoin regimen, resulting in signs of phenytoin toxicity (nystagmus and ataxia). The correct answer is enzyme inhibition by trimethoprim-sulfamethoxazole causing decreased phenytoin clearance because trimethoprim is a known CYP2C9 inhibitor, and phenytoin is primarily metabolized by CYP2C9, leading to decreased clearance and accumulation. Option A incorrectly suggests enzyme induction, which would decrease levels. Option C incorrectly attributes the interaction to omeprazole affecting renal elimination, but phenytoin undergoes minimal renal excretion. Option D incorrectly focuses on volume of distribution, which doesn't explain the toxicity symptoms. The clinical pearl is that CYP450 inhibitors decrease drug clearance, increasing concentrations and risk of toxicity: common phenytoin metabolism inhibitors include trimethoprim, fluconazole, and amiodarone.
15. A 29-year-old woman (weight 58 kg, height 165 cm) with bipolar disorder is taking lithium carbonate. Current medications: lithium carbonate 900 mg/day in divided doses, ibuprofen 600 mg PO three times daily as needed (started 1 week ago), combined oral contraceptive. Medical history: bipolar I disorder, migraines. Allergies: none. Labs: SCr 0.8 mg/dL, lithium level 1.6 mEq/L (goal 0.6–1.2 mEq/L), sodium 138 mEq/L. Which factor is most likely to affect the drug's clearance in this patient?
    Answer: Ibuprofen reducing renal lithium clearance via decreased renal perfusion The pharmacokinetic concept being tested is drug-drug interactions affecting renal clearance of lithium, a narrow therapeutic index drug. The key patient-specific factor is concomitant ibuprofen use, which decreases renal perfusion and lithium clearance via prostaglandin inhibition. Choice A is the best because it correctly identifies ibuprofen's role in reducing lithium excretion, leading to elevated levels and potential toxicity. Choice B is incorrect as oral contraceptives do not induce lithium metabolism; choice C is wrong because migraine history does not alter volume of distribution; choice D is suboptimal as female sex does not increase lithium protein binding. A transferable pearl is to monitor lithium levels closely with NSAIDs, using the formula for clearance Cl = dose / (AUC), and adjust doses to maintain levels 0.6-1.2 mEq/L, anticipating a 20-50% reduction in clearance.
16. A 68-year-old man (weight 78 kg, height 175 cm) with osteomyelitis is started on vancomycin. Current medications: lisinopril 20 mg PO daily, furosemide 20 mg PO daily, acetaminophen 650 mg PO every 6 hours as needed. Medical history: type 2 diabetes, hypertension, chronic kidney disease. Allergies: penicillin (rash). Labs: serum creatinine (SCr) 2.0 mg/dL, AST/ALT within normal limits. The prescriber orders vancomycin 1,250 mg IV every 12 hours; based on this patient's renal function, how should the dosage be adjusted for this patient's renal function?
    Answer: Vancomycin 1,250 mg IV every 24 hours The pharmacokinetic concept being tested is dose adjustment for renally cleared drugs in patients with impaired renal function. The key patient-specific factor is reduced renal clearance, evidenced by a serum creatinine of 2.0 mg/dL and estimated creatinine clearance of approximately 39 mL/min using the Cockcroft-Gault equation. Choice B is the best option because extending the dosing interval to every 24 hours reduces the daily dose to prevent drug accumulation while maintaining therapeutic exposure for osteomyelitis. Choice A increases frequency, risking toxicity from higher peak levels; choice C lowers the dose excessively, potentially leading to subtherapeutic levels; choice D ignores renal impairment, increasing the risk of nephrotoxicity and ototoxicity. A transferable clinical pearl is to always calculate creatinine clearance for vancomycin dosing adjustments in renal impairment, using the formula CrCl = [(140 - age) × weight (kg)] / [72 × SCr (mg/dL)] × 0.85 for females, and for CrCl 30-50 mL/min, initiate 15-20 mg/kg every 24 hours with trough monitoring to target 15-20 mg/L for serious infections.
17. A 47-year-old man (weight 75 kg, height 180 cm) with HIV is stable on antiretroviral therapy and is now prescribed tacrolimus after kidney transplant. Current medications: tacrolimus (new), darunavir/cobicistat, emtricitabine/tenofovir alafenamide. Medical history: HIV, kidney transplant. Allergies: none. Labs: SCr 1.2 mg/dL, AST/ALT normal. Which factor is most likely to affect the drug's clearance in this patient?
    Answer: Cobicistat inhibition of CYP3A decreasing tacrolimus clearance The pharmacokinetic concept being tested is drug-drug interactions via CYP3A inhibition affecting tacrolimus clearance post-transplant. The key patient-specific factor is cobicistat, a strong CYP3A inhibitor in the antiretroviral regimen, reducing tacrolimus metabolism. Choice A is the best because inhibition decreases clearance, increasing tacrolimus levels and requiring dose reductions to prevent toxicity. Choice B is incorrect as tenofovir does not induce CYP3A; choice C is wrong because emtricitabine does not affect renal clearance; choice D is suboptimal as normal enzymes do not negate interactions. A pearl is to reduce tacrolimus dose by 50-90% with strong inhibitors, monitoring troughs with target 5-15 ng/mL, using Cl = dose / (AUC) to guide adjustments.
18. A 66-year-old woman (weight 72 kg, height 162 cm) is on theophylline for COPD. Current medications: theophylline extended-release 300 mg PO every 12 hours, albuterol inhaler as needed. Medical history: COPD, recently quit smoking 2 weeks ago (previously 1 pack/day). Allergies: none. Labs: SCr 0.9 mg/dL, AST/ALT normal. She reports nausea and insomnia; theophylline level is 22 mcg/mL (goal 10–20 mcg/mL). Which factor is most likely to affect the drug's clearance in this patient?
    Answer: Smoking cessation decreasing theophylline clearance and increasing levels The pharmacokinetic concept being tested is changes in hepatic clearance due to lifestyle factors like smoking cessation for CYP1A2 substrates such as theophylline. The key patient-specific factor is recent smoking cessation, which reduces CYP1A2 induction and decreases theophylline clearance, leading to elevated levels. Choice A is the best because it explains the increased exposure causing symptoms like nausea, requiring dose reduction. Choice B is incorrect as albuterol does not induce CYP1A2; choice C is wrong because normal SCr does not indicate increased renal clearance; choice D is suboptimal as formulation does not affect clearance. A pearl is to decrease theophylline dose by 25-50% upon smoking cessation, using clearance Cl = dose / Css, and monitor levels with target 8-15 mcg/mL, calculating half-life $t_{1/2}$ = 0.693 × $V_d$ / Cl.
19. A 52-year-old male (weight 85 kg, height 178 cm) with a mechanical aortic valve is on warfarin. Current medications: warfarin 5 mg PO daily, amiodarone 200 mg PO daily (started 2 weeks ago), levothyroxine 100 mcg PO daily. Medical history: mechanical valve replacement, hypothyroidism. Allergies: none. Labs: INR 4.2 (high; goal 2.5–3.5), AST 26 units/L, ALT 24 units/L. Which factor is most likely to affect warfarin clearance in this patient?
    Answer: Enzyme inhibition by amiodarone causing decreased warfarin clearance This question tests understanding of drug interactions affecting warfarin metabolism through CYP450 inhibition. The key patient-specific factor is the recent addition of amiodarone to stable warfarin therapy, resulting in a supratherapeutic INR of 4.2. The correct answer is enzyme inhibition by amiodarone causing decreased warfarin clearance because amiodarone is a potent inhibitor of multiple CYP enzymes (CYP2C9, CYP3A4, CYP1A2) responsible for warfarin metabolism, leading to decreased clearance and increased anticoagulation. Option A incorrectly suggests enzyme induction, which would decrease INR. Options C and D incorrectly attribute the interaction to levothyroxine affecting renal clearance or absorption, but warfarin undergoes minimal renal excretion and the interaction mechanism is hepatic. The clinical pearl is that amiodarone typically requires a 30-50% warfarin dose reduction due to potent CYP inhibition, with effects persisting weeks after discontinuation due to amiodarone's long half-life.
20. A 45-year-old man (weight 100 kg, height 182 cm) with bacterial meningitis is started on cefepime. Current medications: none. Medical history: chronic kidney disease. Allergies: none. Labs: SCr 3.0 mg/dL. The standard regimen is cefepime 2 g IV every 8 hours in normal renal function. How should the dosage be adjusted for this patient's renal function?
    Answer: Cefepime 2 g IV every 24 hours The pharmacokinetic concept being tested is renal dose adjustment for beta-lactam antibiotics like cefepime in serious infections with impaired kidney function. The key patient-specific factor is chronic kidney disease with SCr 3.0 mg/dL, estimating CrCl ≈34 mL/min and extending half-life. Choice B is the best because 2 g every 24 hours reduces dosing frequency to match decreased clearance, balancing efficacy for meningitis with toxicity risk. Choice A ignores adjustment, causing accumulation; choice C lowers dose but maintains frequency, potentially subtherapeutic; choice D increases frequency, heightening neurotoxicity. A pearl is to use CrCl for adjustments, formula [(140 - age) × weight] / [72 × SCr], and for CrCl 30-60 mL/min, dose cefepime 2 g q12-24h for severe infections, monitoring for seizures.

Start this quiz